Summary: A heterogeneous (solid-phase Separation) fluoroimmunoassay for digoxin in serum was developed employing antibodies coupled to magnetisable cellulose/iron oxide particles and a fluorescein-labelled digoxin derivative s tracer. Intrinsic fluorophores and other potentially interfering components of serum samples were reliably and completely removed at the Separation and wash Steps of the assay procedure which were facilitated by magnetic Sedimentation. In order to attain adequate sensitivity (detec'tion limit 0.2 μg/l (0.26 nmol/1) serum digoxin), a sample volume of 500 μΐ was necessary. Assay results for patients' specimens correlated well with those obtained using established charcoal-separation (r = 0.96) and magnetisable solid-phase (r = 0.95) radioimmunoassays. The feasibility of a "stat" adaptation of the fluoroimmunoassay that involved only two Standards (0.5 and 4 Mg/1 digoxin) was demonstrated. The stat method would be suitable for the assay of urgent or single specimens. 
I-labelled materials have limited shelf-life. In addiDigoxin is the most widely used cardiac glycqside in the tion, there is significant legislative or emotive bias against tre tment of congestive heart failure and cejrtaiii disturb^ the se of radioisotopes in some countries. ances of cardiac rhythm (1) . Dosage must be carefully " ,* i ** n\ ju* ,. . , .
«. J *· Λ ^ rr χ ι-·ι Homogeneous (6, 7, 10, 11) and heterogeneous adjusted to achieve Optimum therapeutic effects while , ΛΛ * . ' ' / CT A\r *· -u •A· * · -4. τι_ ι r ι*··' ΓΛ--(11-13) enzyme-immunoassays(EIA) for digoxin have avoidmgtoxicity.The valueofmonitonngof digoxin ^ j , , , . ι / « -ΛΟΪΑ ii-A '\· -j ι χ "jΓ iJi. u-xt been developed and shown to correlate well with RIA levels in serum (2-4) is widely accepted, altho gh it has ,, _ , Λ Λ ** ττ χ , . r been pointed out that the usefolness of such meEure-< 6 ' 1\ ll > «)· Ho««w, the measurement of enzyme ments in the diagnosis of drug-related toxicity has not &< * ινι * «ff« of ^ '^woassay may reqmre extra beenconclusivel y proven (5) .Radioimmunoassays(RIA) , reagent.add.t.on Steps ormanipulation to Start or stop employing 3 H-labelled digoxin (2, 4, 6) digoxin derivative (6-9) s tracer are most commonly g· 7 « 12) '^d r^*lve y l?ng mcubation times used. The latter have many advantages including thei? < between 30 and 60 mm for the ^ο χιη «"^)· high sensitivity (low sample volume requirement) and Fluoroimmunoassay (FIA) techniques have the advantage the convenience of gamma-radiation counting, but that fluorescence may be measured simply and rapidly.
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This report describes an F1A for serum digoxin that employs antibodies coupled to magnetisable solidphase particles and a fluorescein-labelled digoxin derivative äs tracer. The "sequential addition" procedure (14) , in which the antibody reagent is first incubated with the sample and then separately with the tracer, was adopted. 
Coupling of di-(O-carboxymethyl)oxime derivative to fluoresceinthiocarbamyl ethylenediamine
l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (9.5 mg) and N-hydroxysuccinimide (0.5 mg) were dissolved in l ml of dimethylformamide. pi-(O-carboxymethyl)oxime sölution (400 ) was ädded and the reaction mixture stirred for l h. To the resulting active ester solütiori was added dropwise 500 of a 4 g/l sölution of fluoresceinthiocarbafhyl ethylenediamine in dimethylformamide. After stirring for a further f 20 min, the reaction mixture was applied to silica-gel sheets (250 per sheet) which were developed with chloroform/methanol/ ammonia (40 + 30 + 5 by volume) to separate three yellöw-örange products (designated A, B, and C) with Rf values 0.76, 0.50, and 0.40, respectively. (Fluoresceinthiocarbarnyl ethylenediamine had Rf 0.05 in this System.) The area of each product was scraped from the sheets, the scrapings eluted with l ml of methanol per sheet, and the eluates stored in the dark at 4 °C. 
Dialdehyde derivative
Digoxin or digoxigenin bis-digitoxoside (50 mg) was dissolved in a mixture of 3 ml of methanol and l ml of Chloroform. To the stirred sölution was added dropwise 500 of 10 g/l aqueous sodium metaperiodate. Stirring was continued for 45 min, then the reaction mixture was evaporated to dryness under a stream of nitrogen. Chloroform (3 ml) was added to the residue and shaken thoroughly. The Chloroform extract was separated from the inorganic solids, 100 mg of anhydrous magnesium sulphate added, and the mixture stood for l h. The Chloroform layer was again separated from the solids and evaporated to dryness under nitrogen. The product was dissolved in ethanol to 25 g/l. Thinlayer chromatography with the solvent System Chloroform/ methanol (9 +1 by volume) showed one cpmponent at Rf 0.50 (detected by spraying with methanol/concentrated sulphuric acid (9 + 1 by volume) and warming briefly to develop a grey-brown colour).
Di-(O-carboxymethyl)oxime derivative
Sodium acetate (30 mg) and carboxymethoxylamine hemihydrochloride (35 mg) were dissolved in 150 of water in a 5 ml round-bottomed flask. Dialdehyde sölution (l ml) was ädded and the reaction mixture refluxed on a boiling water bath for l h. The course of reaction was followed by thin-layer chromatography using chloroform/acetone/glacial acetic acid (7 + 2 + 1 by volume). A single major product appeared at Rf 0.16 (detected with methanol/sulphuric acid äs described above). The reaction mixture was reduced to a small volume under a stream of nitrogen, diluted with l ml of water, then extracted twice with 2 ml of ethyl acetate. The organic extracts were combined and dried over anhydrous magnesium sulphate. The ethyl acetate layer was separated from the solids and evaporated to dryness under nitrogen. The product was dissolved in dimethylformamide to 10 g/l.
Fluoresceinthiocarbamyl ethylenediamine Prepared äs described previously (15).
Fluoroimmunoassay Standards A sölution pf digoxin in ethanol (250 mg/1) was diluted in pooled normal human serum. Standards were stored at -20' 'C.
Patients' specimens Serum specimens were taken at random from those submitted for digoxin assay to the Routine Laboratory, Department of Chemical Pathology, St. Bartholomew's Hpsjpital, London EC1, U.K. (Plasma specimens were not suitable for assay by FIA because of a tendency to aggregate the solid-phase particles).
Radioimmunoassay procedures Digoxin levels in patients' specimens were determined in the Hospital laboratory by a charcoal-separatioii RIA employing 125 I-läbelled digoxin. The specimens were also assayed using magnetisable solid^phase RIA kits with 125 I-tracer (Technia Diagnostics), which were used according to the manufacturer's instructions.
Fluoroimmunoassay procedures Düuent buffer
Sodium borate buffer (200 mmol/1, pH 9.5) containing l g/l bovine albumin and l g/l sodium azide.
Wash buffer
Sodium borate buffer (20 mmol/1, pH 9.5) containing l gA bovine albumin and l g/l sodium azide. (14) .
Test tubes

Assay protocol
All operations were performed at room temperature, in duplicate. Serum samples (500 μΐ) were dispensed into test tubes. To each tube was added 100 μΐ of anti-digoxin solid-phase Suspension (12 g/l in diluent buffer). Tlie tubes were vortexed and incubated for 20 min with a vortex after 10 min to prevent excessive gravitationaJ settling of the solid-phase particles. The rack containing the tubes was placed on the magnet and the solid phase allowed to sediment magnetically over about 5 min, then the supernatants were aspirated to waste. Wash buffer (1.5 ml) was added, the tubes vortexed, and the solid phase again sedimented on the magnet and the supernatants aspirated to waste. To each tube was added 100 μΐ of digoxin tracer (33 nmol/l in diluent buffer). The tubes were vortexed and incubated for 20 min with a vortex after 10 min. Wash buffer (1.5 ml) was added, the tubes vortexed, and the solid phase sedimented on the magnet. The fluorescence of the supernatants was measured by placing each test tube directly in the fluorimeter.
Results
Characterisation of digoxin tracer
Fluorescent tracer products A, B, and C were assessed by measurement of immunoreactivity using excess antidigoxin solid phase. Values of 55,70, and 40%, respectively, were obtained for tracers prepared from either digoxin or digoxigenin bis-digitoxoside. Typical concentrations of product Solutions in methanol were 15,60, and 45 μτηοΐ/ΐ, respectively. Product B was accordingly chosen for use in the FLA. No attempt was made to characterise further the various tracer products.
The results described below were obtained with a tracer prepared from digoxigenin bis-digitoxoside. However, tracer prepared by labelling digoxin behaved identically in the FIA.
Assay r nge and detectability of digoxin The FIA covered the clinically important therapeutic and toxic concentration ranges (2-4) for digoxin (flg. 1). The minimal detectable concentration (17) of digoxin in serum at the 95% confidence level was 0.2 /ig/l (0.26 nmol/l). The minimal detectable dose (17) was 0.1 ng (0.13 pmol) of digoxin per tube.
Precision Within-assay precision was assessed by measuring each of three serum specimens 10 times in duplicate, giving mean results l .1,2.2, and 3.1 μg/^, with coefficient of Variation (CV) of 9.6,4.5, and 4.2%, respectively. Assay of the same specimens in duplicate on each of 10 different days gave between-assay CV results of 12.6,6.6, and 4.2%, respectively.
Recovery
Digoxin was added at different levels to each of two specimens of normal human serum. Analytical recovery of l μg/l added digoxin was 90.5 and 107.5% and that of 2.5 Mg/1 added digoxin was 92 and 102%.
Specificity
Cross-reactivities of various substances in the digoxin FIA were determined by the method of Abraham (18) in which the amount of digoxin required to cause 50% displacement of tracer from antibody is expressed s a percentage of the amount of cross-reactant required to produce the same effect. The digoxin metabolites digoxigenin bis-digitoxoside, digoxigenin mono-digitoxoside, digoxigenin, and dihydrodigoxin crossfeacted to 100,100,90, and 12%, respectively, and the related drugs lanatoside C, digitoxin, gitoxin, and ouabain to 96,3.4, 2.0, and 0.03%, respectively. No detectable interference at a serum level of l g/l was found with spironolactone, but its metabolites canrenone and canrenoate cross-reacted to l .2 and 0.06%, respecfively. No detectable cross-reaction at the l g/l level was found with amiodarone, cholesterol, cortisol, disopyramide, oestriol, lidocaine, procainamide, progesterone, propranolol, quinidine, or testosterone. "Stat" assay procedure
When plotted with a linear concentration scale, the FIA Standard curve showed extensive linearisation ( fig. 4 ) which was consistently reproducible between digoxin levels of 0.5 and 4 g/l. A stat assay procedure was devised in which only two Standards with these concentrations were emplqyed and the Standard curve was constructed by drawing a straight line between the corresponding points. Results for the assay of 48 patients' specimens calculated by the stat FIA method (y) and by the normal FIA procedure with füll Standard curve (x) were related by the regressipn line y = 1.03 x, with r = 0.998.
Stabil-ity of fluoroimmunoassay reagents
Digoxin tracer preparations stored in methanol showed no change in properties over at least one and a half years, and anti-digoxin solid phase and digoxin serum Standards were stable for at least two years. 
Discussion
A clinically useful digoxin assay should cover the commonly encpuntered therapeutic and toxic concentrations whieh Ue (2-^4) in the ränge 0.5 to S ^/1 (0,6 to 6 nmpl/1). Such drug levels are easily determined by RIA employing lis l-träcer (6) (7) (8) (9) . However, it is apparent that this coneentration ränge represeiits the practical Ümit of homogenepus § since for digoxin assay a sample volume of 200 and an incubation period of 30 min are required (6,7,10) to achieve a detection limit of 0.64 nmol/1 (l 1), and sample pretreatment with strong alkali (6,11) is necessary to prevent interference by endogenous serum constituents such äs certain dehydrogenases (l 1). In heterogeneous EIA (11) (12) (13) , sample interferences are removed in a Separation step; one such assay, which has a detection limit of 0.4 nmol/1 digoxin (11, 12) , requires 100 of sample and a 60 min incubation period for quantitation of antibody-bound enzyme-labelled digoxin (12) .
As compared with the determination of enzyme activity, the measurement of fluorescence is rapid and simple; in FIA studies in this laboratory, fluorescence readings are routinely taken in five seconds using the signal-averaging facility of the Perkin-Elmer Instrument.
As previously demonstrated (14), fluorescence of supernatants above sedimented solid phase may conveniently be determined directly in disposable polystyrene assay tubes. In the digoxin FIA, the use of a heterogeneous assay technique enables the reliable and complete removal of serum fluorophores and other potentially interfering components at the aspiration stages, while the Separation Steps are facilitated by magnetic Sedimentation. A general property öf the sequential addition procedure adopted in this work is that tracer and sample are never in contact, and therefore non-specific serum binding interferences are entirely obviated.
It was found that a sample volume of 500 was necessary to attain acceptable sensitivity in the FIA (detection limit 0.26 nmol/1 serum digoxin). Urider the fluorimetric conditions used, the background Signal (consisting of fluorescent and scättered light from the wash buffer and the test tubes) amounted to about 10% of the total tracer Signal, and it was judged that further significant improvement of assay sensitivity by dilution of the tracer reagent (and the solid-phase antl· body) was not feasible. Curry et al. (20) have described a solid-phase FIA fof triiodothyronine that employs the fluoresceinrlabelled hörmone äs tracer, requires a sample volume of 100 , and has a detection limit of 03 nmol/1. Together with the present results, this suggests that FIA employiiig antigen labelled with a single fluorophore and with quantitatiorj of this tracer by cpnventjonal fluorimetry may be generally suitable for assay of serum analy tes down to concentrations of a few nanomoles per litre. Further sensitivity improvement in FIA might require, for example, the applicätion of multi-flüoro-phore-labelliiig techniques (21-24).
The term "stat" is usually applied to simplifled or speeded test procedures that are suitable for assay of urgent or single specimens. Stat adaptations of digoxin RIA methods (8, 9) have included reduction in the number of calibrators so that the Standard curve is plotted with three points orily. Einergency modifications of hömogeneous (6) and heterogeneous (12) digoxin EIA involving only two serum Standards have been proposed. A stat FIA requiring only two Standards and relying on linearisation of the Standard curve ( fig. 4 ) was tested. Good correlation of assay results with those obtained using a füll Standard curve indicated the basic feasibility of this approach, but it was not an aim of these studies to perform füll validation (precision, etc.) of the stat assay. In clinical applicätion of any such method, the inclusion of qualitycontrol specimens in each assay run would be necessary, in accord with normal practice, äs a confirmation of accuracy (8) .
The digoxin FIA employs stable, non-radioactive reagents and may be performed using a simple filter fluorimeter. Using the stat procedure, a result for an urgent specimen could be obtained within about l h. The assay requires a relatively large sample volume which could be a disadvantage in some circumstances. However, it was found that the majority of specimens submitted to the Hospital laboratory häd a volume greater than l ml and were therefore suitable for duplicate determination by FIA. Although the FIA correlated acceptably with two established RIA methods, the cross-reactivity of canrenone and canrenpate would suggest that in its present form it is unsuitable for assay of specimens from patients receiving spironolactone äs well äs digoxin. A similar pröblem in heterogeneous EIA was overcome by a change to a more specific antiserum reagent (12) and this would presumably also be effective in the FIA systerri.
